Skip to Content
David F Jarrard, MD

Contact Dr. Jarrard

E-mail:
jarrard@urology.wisc.edu

Phone:
(608) 262-0759

Mail:
UW Medical Foundation Centennial Building
1685 Highland Ave
MADISON, WI 53705-2281

David F Jarrard, MD

Vice Chair for Clinical Affairs
Professor of Urology
John Livesey Chair in Urologic Oncology
Associate Director, UW Carbone Cancer Center

Education

  • MD, University of Virginia School of Medicine, Charlottesville, VA, 1989
  • Junior Residency in General Surgery, University of Chicago, Chicago, IL, 1989-1990
  • Residency in Urology, University of Chicago, Chicago, IL, 1990-1994
  • Fellow in Urologic Oncology, American Foundation for Urologic Disease, Johns Hopkins University, Baltimore, MD, 1994-1996

Clinical Specialties

Dr. Jarrard is board certified by the American Board of Urology and has completed a fellowship in Urologic Oncology. He specializes in all aspects of urologic oncology with an emphasis on prostate cancer diagnosis and treatment including robotics.

Research Interests

Dr. Jarrard has a joint appointment with the University of Wisconsin Comprehensive Cancer Center, and his clinical research emphasizes developing novel diagnostics and new therapies for genitourinary cancers. He has an active basic science laboratory and is funded through the National Institutes of Health and Department of Defense to examine genetic and epigenetic alterations in prostate cancer.

Dr. Jarrard's lab

Funding/Grants
  • The Induction of Cellular Senescence as Therapy for Advanced Prostate Cancer
    Funding Agency: Prostate Cancer Foundation
    Principal Investigator(s): David F Jarrard, MD
    More Information

Recent Publications
  • Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, DiPaola RS, Sweeney CJ. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J. Clin. Oncol. 2018 Jan 31; ():JCO2017753657.
    [PubMed ID: 29384722]
    More Information
  • Johnson BP, Vitek RA, Geiger PG, Huang W, Jarrard DF, Lang JM, Beebe DJ. Vital ex vivo tissue labeling and pathology-guided micropunching to characterize cellular heterogeneity in the tissue microenvironment. BioTechniques 2018 Jan 01; 64(1):13-19.
    [PubMed ID: 29384072]
    More Information
  • Richards KA, Ruiz VL, Murphy DR, Downs TM, Abel EJ, Jarrard DF, Singh H. Diagnostic evaluation of patients presenting with hematuria: An electronic health record-based study. Urol. Oncol. 2017 Nov 20.
    [PubMed ID: 29169843]
    More Information
  • Damodaran S, Kyriakopoulos CE, Jarrard DF. Newly Diagnosed Metastatic Prostate Cancer: Has the Paradigm Changed? Urol. Clin. North Am. 2017 Nov; 44(4):611-621.
    [PubMed ID: 29107277]
    More Information
  • Lee JH, Yang B, Lindahl AJ, Damaschke N, Boersma MD, Huang W, Corey E, Jarrard DF, Denu JM. Identifying Dysregulated Epigenetic Enzyme Activity in Castrate-Resistant Prostate Cancer Development. ACS Chem. Biol. 2017 11 17; 12(11):2804-2814.
    [PubMed ID: 28949514]
    More Information
  • Damaschke NA, Yang B, Bhusari S, Avilla M, Zhong W, Blute ML, Huang W, Jarrard DF. Loss of Igf2 Gene Imprinting in Murine Prostate Promotes Widespread Neoplastic Growth. Cancer Res. 2017 Oct 01; 77(19):5236-5247.
    [PubMed ID: 28775169]
    More Information
  • Maciolek KA, Jarrard DF, Abel EJ, Best SL. Systematic Assessment Reveals Lack of Understandability for Prostate Biopsy Online Patient Education Materials. Urology 2017 Nov; 109():101-106.
    [PubMed ID: 28780302]
    More Information
  • Wang JH, Downs TM, Jason Abel E, Richards KA, Jarrard DF. Prostate Biopsy in Active Surveillance Protocols: Immediate Re-biopsy and Timing of Subsequent Biopsies. Curr Urol Rep 2017 Jul; 18(7):48.
    [PubMed ID: 28589399]
    More Information
  • Blute ML, Kucherov V, Rushmer TJ, Damodaran S, Shi F, Abel EJ, Jarrard DF, Richards KA, Messing EM, Downs TM. Reduced estimated glomerular filtration rate (eGFR <60 mL/min/1.73 m2 ) at first transurethral resection of bladder tumour is a significant predictor of subsequent recurrence and progression. BJU Int. 2017 Sep; 120(3):387-393.
    [PubMed ID: 28464520]
    More Information
  • Tazeh NN, Canter DJ, Damodaran S, Rushmer T, Richards KA, Abel EJ, Jarrard DF, Downs TM. Neutrophil to Lymphocyte Ratio (NLR) at the Time of Transurethral Resection of Bladder Tumor: A Large Retrospective Study and Analysis of Racial Differences. Bladder Cancer 2017 Apr 27; 3(2):89-94.
    [PubMed ID: 28516153, PMCID: 5409044]
    More Information


webmaster@surgery.wisc.edu Copyright © 2018 The Board of Regents of the University of Wisconsin System